title: A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial.
abstract: BACKGROUND
  Everolimus is a sirolimus analogue with similar efficacy in animal models, and has been previously successfully tested in humans using an erodable polymer.
  
  
  METHODS
  This first-in-man single blind multi-centre randomized controlled trial assessed the safety and efficacy of everolimus eluting from a durable polymer on a cobalt chromium stent in patients with de novo native coronary artery lesions. Sixty patients were allocated to stent implantation with an everolimus-eluting stent (n=28) or an identical bare stent (n=32). Patients had either stable, unstable angina or silent ischaemia. Suitable lesions treated were single de novo native coronary lesions with 50-99% stenosis and could be covered by a 18 mm stent. The primary endpoint was in-stent late loss at 180 days, analysed on a per treatment basis. The major secondary endpoint was percent in-stent volume obstruction (%VO) as measured by intravascular ultrasound (IVUS) at 180 days. The clinical secondary endpoint was major adverse cardiac events (MACE) at 180 days.
  
  
  RESULTS
  At 6 months, (matched pairs angiographic analysis), the in-stent late loss, percentage diameter stenosis and percentage of patients with binary restenosis were 0.10 mm, 16% and 0% respectively, in the everolimus arm (n=23), as compared with 0.87 mm, 39% and 25.9%, respectively in the bare stent arm (n=27, p<0.001 for late loss and diameter stenosis, p = 0.01 for restenosis). Significantly less neointimal hyperplasia was observed in the everolimus group compared to the bare stent group (10 +/- 13 mm3 vs 38 +/- 19 mm3, p<0.001) and similarly, less volume obstruction (8.0 +/- 10.4% versus 28.1 +/- 14.0%, p<0.001). A major adverse cardiac event occurred in 2 patients in the everolimus arm versus 6 in the bare stent arm.
  
  
  CONCLUSIONS
  Everolimus eluted from a durable polymer on a cobalt chromium stent effectively suppresses neointimal growth at 6 months compared to an identical bare stent.
authors.affiliation: Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
authors.forename: Andrew T L
authors.initials: AT
authors.lastname: Ong
authors.forename: Jan J
authors.initials: JJ
authors.lastname: Piek
authors.forename: Franz-Josef
authors.initials: FJ
authors.lastname: Neumann
authors.forename: Willem J
authors.initials: WJ
authors.lastname: van der Giessen
authors.forename: Marcus
authors.initials: M
authors.lastname: Wiemer
authors.forename: Andreas
authors.initials: A
authors.lastname: Zeiher
authors.forename: Eberhard
authors.initials: E
authors.lastname: Grube
authors.forename: Jürgen
authors.initials: J
authors.lastname: Haase
authors.forename: Leif
authors.initials: L
authors.lastname: Thuesen
authors.forename: Christian
authors.initials: C
authors.lastname: Hamm
authors.forename: Patricia C
authors.initials: PC
authors.lastname: Otto-Terlouw